BR112021026551A2 - Ativador de função mitocondrial - Google Patents
Ativador de função mitocondrialInfo
- Publication number
- BR112021026551A2 BR112021026551A2 BR112021026551A BR112021026551A BR112021026551A2 BR 112021026551 A2 BR112021026551 A2 BR 112021026551A2 BR 112021026551 A BR112021026551 A BR 112021026551A BR 112021026551 A BR112021026551 A BR 112021026551A BR 112021026551 A2 BR112021026551 A2 BR 112021026551A2
- Authority
- BR
- Brazil
- Prior art keywords
- mitochondrial function
- function activator
- activator
- present
- pharmaceutical agent
- Prior art date
Links
- 230000004898 mitochondrial function Effects 0.000 title abstract 4
- 239000012190 activator Substances 0.000 title abstract 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 abstract 2
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 abstract 2
- 239000008177 pharmaceutical agent Substances 0.000 abstract 2
- 239000004471 Glycine Substances 0.000 abstract 1
- 229940000635 beta-alanine Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/06—Anabolic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Ophthalmology & Optometry (AREA)
- Psychiatry (AREA)
- Child & Adolescent Psychology (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Vascular Medicine (AREA)
Abstract
ativador de função mitocondrial. o objetivo da presente invenção consiste em fornecer um agente farmacêutico que ativa função mitocondrial, particularmente, um agente farmacêutico não dispendioso. o problema pode ser resolvido por um ativador de função mitocondrial da presente invenção, que compreende ß-alanina ou glicina, ou um sal das mesmas.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2019121874 | 2019-06-28 | ||
PCT/JP2020/023600 WO2020262114A1 (ja) | 2019-06-28 | 2020-06-16 | ミトコンドリア機能活性化剤 |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112021026551A2 true BR112021026551A2 (pt) | 2022-02-15 |
Family
ID=74060145
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112021026551A BR112021026551A2 (pt) | 2019-06-28 | 2020-06-16 | Ativador de função mitocondrial |
Country Status (6)
Country | Link |
---|---|
US (1) | US20220313639A1 (pt) |
EP (1) | EP3991790A4 (pt) |
JP (1) | JPWO2020262114A1 (pt) |
CN (1) | CN114302718A (pt) |
BR (1) | BR112021026551A2 (pt) |
WO (1) | WO2020262114A1 (pt) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023106325A1 (ja) * | 2021-12-07 | 2023-06-15 | 有機合成薬品工業株式会社 | β-アラニン吸収抑制剤 |
JP7319445B1 (ja) | 2022-11-11 | 2023-08-01 | ザ コカ・コーラ カンパニー | 飲料、及び飲料の塩味を改善する方法 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3081215B9 (en) * | 2005-05-23 | 2020-08-19 | Natural Alternatives International, Inc. | Compositions and methods for the sustained release of beta-alanine |
JP6199579B2 (ja) | 2013-02-28 | 2017-09-20 | 三宅 正治 | ミトコンドリア機能回復促進剤 |
JP6478307B2 (ja) * | 2013-11-19 | 2019-03-06 | 国立大学法人九州大学 | ミトコンドリア活性化剤 |
AU2016268340B2 (en) * | 2015-05-28 | 2021-07-08 | Baylor College Of Medicine | Benefits of supplementation with N-acetylcysteine and glycine to improve glutathione levels |
EP3439491A1 (en) * | 2015-12-13 | 2019-02-13 | Verburgh, Kris | Methods and compositions to slow down aging in cells and organisms |
-
2020
- 2020-06-16 WO PCT/JP2020/023600 patent/WO2020262114A1/ja active Application Filing
- 2020-06-16 BR BR112021026551A patent/BR112021026551A2/pt not_active Application Discontinuation
- 2020-06-16 JP JP2021528263A patent/JPWO2020262114A1/ja active Pending
- 2020-06-16 US US17/597,148 patent/US20220313639A1/en active Pending
- 2020-06-16 EP EP20832118.2A patent/EP3991790A4/en active Pending
- 2020-06-16 CN CN202080061222.8A patent/CN114302718A/zh active Pending
Also Published As
Publication number | Publication date |
---|---|
JPWO2020262114A1 (pt) | 2020-12-30 |
EP3991790A4 (en) | 2023-10-25 |
US20220313639A1 (en) | 2022-10-06 |
EP3991790A1 (en) | 2022-05-04 |
CN114302718A (zh) | 2022-04-08 |
WO2020262114A1 (ja) | 2020-12-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112022012891A2 (pt) | Instrumento cirúrgico compreendendo sistema de detecção | |
BR112021026551A2 (pt) | Ativador de função mitocondrial | |
CL2021000039A1 (es) | Moléculas de anticuerpo que se unen a cd73 y usos de las mismas (divisional solicitud 201903796) | |
BR112017025749A2 (pt) | suporte de seringa e autoinjetor | |
BR112015015642A2 (pt) | método para personalizar um modo de cena de um dispositivo inteligente | |
BR112016024163A2 (pt) | trava de segurança de captura de agulha para catéter | |
BR112016029080A2 (pt) | sistemas de travamento de fechamento para instrumentos cirúrgicos | |
BR112018075498A8 (pt) | Planejamento e controle de operações agrícolas autônomas | |
BR112017003270A2 (pt) | inércia paramétrica e apis | |
BR112019010115A8 (pt) | Método de proporcionar benefícios de higiene bucal | |
BR112018072454A2 (pt) | composição de tratamento de superfície antiferrugem aquosa e membro de metal com superfície revestida | |
BR112017003730A2 (pt) | tubo em camadas | |
BR112016024773A2 (pt) | dispositivo de direcionamento para travamento distal de pinos intramedulares e métodos de uso | |
BR112018011168A2 (pt) | luz divergente do sistema de entrega de iluminação de elemento óptico de fibra | |
BR112018071792A2 (pt) | robô móvel com capacidades de movimento equilibrado e de comportamento melhoradas | |
BR112018007395A2 (pt) | 2,4-di-hidróxi-nicotinamidas como agonistas de apj | |
BR112016006428A2 (pt) | anticorpo, fragmento de ligação a antígeno do anticorpo, composição farmacêutica, métodos para tratamento e/ou profilaxia de infecção por pseudomona e para produzir um anticorpo, agente de diagnóstico para infecção por pseudomona, kit de detecção para pseudomonas aeruginosa, polinucleotídeo, vetor, e, célula hospedeira transformada | |
BR112017023574A2 (pt) | dispositivo de segurança para seringas pré-cheias | |
BR112019004990A2 (pt) | anticorpo que se liga especificamente a il-17a e fragmento funcional do mesmo | |
BR112016030088A2 (pt) | sistema para uma máquina de escavação | |
CL2019002873A1 (es) | Moduladores del receptor x del hígado (lxr). | |
BR112017025639A2 (pt) | brinquedo de transformação | |
BR112019005759A2 (pt) | processamento de imagem em um veículo autônomo não tripulado | |
BR112015024502A2 (pt) | complexo de polipeptídeo de cadeia de açúcar | |
AR104912A1 (es) | Sistema de fijación de miembro de desgaste para instrumento de excavación |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |